Navigation Links
FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US
Date:7/20/2011

WILMINGTON, Del., July 20, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has approved BRILINTA™ (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/astrazeneca/50355/

BRILINTA, a new oral antiplatelet medicine, is indicated to reduce the rate of thrombotic cardiovascular events in patients with ACS (unstable angina [UA] non-ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). BRILINTA has been shown to reduce the rate of a combined endpoint of CV death, MI or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with an artery-opening procedure known as percutaneous coronary intervention (PCI), BRILINTA reduces the rate of stent thrombosis. BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin above 100 mg daily.

David Brennan, Chief Executive Officer, AstraZeneca said: "The FDA approval of BRILINTA is good news for patients in the United States and represents a significant milestone as we seek to help ensure ACS patients around the world have access to this innovative medicine. With over one million people affected by ACS in the US each year, the fact that physicians have a new and more effective treatment option than clopidogrel to help reduce the rate of heart attack and cardiovascular death in these patients is an important adv
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Vaccines for the 2011-2012 Influenza Season
2. FDA Approves Boostrix to Prevent Tetanus, Diphtheria, and Pertussis in Older People
3. FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease
4. FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
5. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
6. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
7. FDA Approves Nulojix for Kidney Transplant Patients
8. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
9. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
10. FDA Approves Redesigned Labels for Some Merck Drugs
11. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Trial to Examine Safety and Efficacy of DARA ... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced the initiation of a Phase 2b,clinical ... candidate.,This randomized, double-blind, placebo and active-controlled,parallel-group study is ...
... 29 A study reported in,the journal ... the,Ciliary Neurotrophic Factor gene (CNTF) may affect ... Vanda Pharmaceuticals,Inc., included patients with acute symptoms ... (iloperidone), a novel atypical,antipsychotic agent currently under ...
Cached Medicine Technology:Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 4Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... discovery by Northwestern Medicine scientists could lead to potential ... in people with scleroderma. , Fibrosis, or scarring, ... of the skin and lungs can lead to serious ... concept for new therapeutic options centers on findings made ... who identified the role that a specific protein plays ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... Featured March 7-12 in San Diego FAIRFAX, ... Radiology (SIR) will present the latest research on ... cancer; herniated disks; peripheral arterial disease (PAD) and ... 34th Annual Scientific Meeting, March 7-12 at the ...
... Feb. 25 Mark Leventhal, Esq., the Founder and ... in the nation executive weight loss consulting service for ... County (OH) Bar Association at 11:45 am today at ... Leventhal Consulting takes a one-on-one personalized approach, and works ...
... Deborah Way, MD, of The Visiting Nurse Association of ... in hospice and palliative medicine from the American Board ... medical director of VNA,s Hospice of Philadelphia which provides ... in the Greater Philadelphia region.ABIM works to enhance the ...
... the country to confront the challenge of eating disordersNational Eating ... a note from my mom on the kitchen table when ... you have bulimia. We need to talk.," (EXCERPT ... the right way to discuss an eating disorder with a ...
... much of the state of California during mid- to ... many regions of the State. A study conducted by ... Natural Resources Defense Council, and the California Department of ... had a substantial impact on morbidity throughout California, resulting ...
... VEGAS, Feb. 25 From children to ... life every day. The focus of the American ... Advertising Campaign is on preventing and healing joint pain, ... athletes, knees. The AAOS is committed to helping ...
Cached Medicine News:Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 3Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 4Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 5Health News:Mark Leventhal to Address the Lake County (OH) Bar Association 2Health News:Hospice of Philadelphia Medical Director, Deborah Way, MD, Earns Certification from the American Board of Internal Medicine 2Health News:The Renfrew Center Foundation Partners with 2008 Miss America Kirsten Haglund and Her Mom, Iora Haglund, to Empower Parents to Fight Eating Disorders 2Health News:The Renfrew Center Foundation Partners with 2008 Miss America Kirsten Haglund and Her Mom, Iora Haglund, to Empower Parents to Fight Eating Disorders 3Health News:Study analyzes 2006 California heat wave's substantial effect on morbidity 2Health News:Study analyzes 2006 California heat wave's substantial effect on morbidity 3Health News:The Most Breaking News in the Joint 2Health News:The Most Breaking News in the Joint 3Health News:The Most Breaking News in the Joint 4
... Soft, foam-lined FoamWrap ThumWrap Splints offer support ... Ideal to relieve mild pain or strain ... activities. Choose either the rigid or the ... amount of support. Washable and breathable, the ...
... lightweight orthosis is designed to comfortably restrict ... holding the hand in a neutral position. ... grade thermoplastic whose unique characteristics offer durable ... provides rigid cast-like immobilization of the wrist, ...
... is a custom wrist orthotic designed to limit the ... patient's maximum range-of-motion. , ,Indications: , Wrist ... fibrocartilage complex , Coles fracture - distal ... Partial tendon rupture , ORIF - Open ...
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
Medicine Products: